Iovance Biotherapeutics, Inc.
NASDAQIovance Biotherapeutics enters September with a striking reversal in its short book — the same bears that were quietly retreating two weeks ago have snapped back hard, and the options market has shifted its tone to match. The short interest story has changed materially since the last note. Short interest climbed 16.8% on the week to 25.8% of the free float — roughly 102.5 million…
A new long-form analysis for IOVA this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumIovance Biotherapeutics enters September with a striking reversal in its short book — the same bears that were quietly retreating two weeks ago have snapped back hard, and the options market has shifted its tone to…
Snapshot as of 20 Sept 2026
Iovance Biotherapeutics gave back 7.8% on Friday to close at $8.29, yet still logged an 18.8% gain on the week — and the most notable shift in the data this week is not in the short book but in options, where defensive…
Iovance Biotherapeutics has now climbed 41% in a month and the Street is finally chasing it higher — yet the short book, week after week, refuses to break. The most notable development this week is on the analyst side.…
Iovance Biotherapeutics is now up 41% in a single month and the short book, while trimming at the margins for a third consecutive week, remains one of the heaviest in biotech — a standoff that continues to define the…
Iovance Biotherapeutics is now up 78% in a single month and the short book, despite a week of further trimming, remains one of the heaviest in biotech — a standoff that grows more expensive for bears with each passing…
Iovance Biotherapeutics enters the new week in a genuinely unusual position — a stock up 55% in five days that still carries one of the heaviest short books in biotech, with options traders now at their most defensive…
Iovance Biotherapeutics just delivered one of the biggest single-day pops in its history — yet the short book is rebuilding, options defensiveness is at a year-high, and the borrow market is tightening in real…
Iovance Biotherapeutics heads into the week with a contradictory setup — short interest has fallen sharply over the past month, yet options traders are showing the most defensive tilt in months at the same time the…
Iovance Biotherapeutics heads into its August 6 earnings print with short sellers largely dug in — covering has stalled, the stock has given back its momentum, and options traders are quietly turning more…
Iovance Biotherapeutics enters the week of July 18 carrying one of the more interesting tensions in small-cap biotech: a stock up 31% in a month, yet still carrying 26% of its free float sold short — and shorts have…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IOVA — free to start on ORTEX.
Sign up for free →Open IOVA on ORTEX